On ECHEMI
Home > Drugs > Escherichia coli pneumonia
Escherichia coli pneumonia
Escherichia coli pneumonia has increased significantly in recent years. It is the second most common pathogen causing community-acquired Gram-negative pneumonia after Klebsiella pneumoniae, accounting for 12% to 45% of Gram-negative pneumonia and 2.0% to 3.3% of all pneumonia pathogens. It is one of the main pathogens of hospital-acquired pneumonia, with an incidence of 4.2 to 9.0/10,000, accounting for 9.0% to 15.0% of Gram-negative pneumonia. The mortality rate of the disease was as high as 60% in the 1960s, and it dropped significantly after the 1980s, with a reported rate of 29%. It mainly occurs in elderly frail patients, those with various chronic underlying diseases, critically ill patients, endotracheal intubation, long-term use of corticosteroids and other immunosuppressants, long-term use of antibiotics resulting in dysbacteriosis, and patients with various immunoglobulin deficiencies, who are susceptible to this disease.
  • Site of disease:

    lung
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    Cough sputum chest pain sticky or purulent sputum with fishy odor sticky or purulent sputum with fishy odor
Related Drugs
Amoxicillin and clavulanate potassium dispersible tablets
Indication: This product can be used to treat infections caused by sensitive strains of microorganisms specified in the following conditions: 1. Lower respiratory system infections: caused by β-lactamase-producing bacteria Haemophilus or Moraxella. 2. Otitis media: caused by β-lactamase-producing bacteria Haemophilus or Moraxella. 3. Sinusitis: caused by β-lactamase-producing bacteria Haemophilus or Moraxella. 4. Skin and skin soft tissue infections: caused by β-lactamase-producing bacteria Staphylococcus, Escherichia coli or Klebsiella. 5. Urinary tract infections: caused by Escherichia coli, Klebsiella or Enterobacter. Although this product is effective for the above infections, infections caused by ampicillin-sensitive bacteria can also be treated with this product because it contains amoxicillin. Therefore, this product is effective for complex infections caused by ampicillin-sensitive microorganisms and β-lactamase-producing microorganisms, and no other antibiotics are needed. Because amoxicillin is more effective than ampicillin and penicillin against Streptococcus pneumoniae in vitro, the vast majority of Streptococcus pneumoniae that are sensitive to ampicillin or penicillin are completely sensitive to amoxicillin and this product. In order to detect the pathogenic bacteria and their sensitivity to this product, bacteriological tests should be performed together with surgical operations. When the infection may involve the above-mentioned microorganisms that produce β-lactamases, treatment must be started before the results of bacteriological and sensitive tests are obtained in order to measure the pathogenic bacteria and their sensitivity to this product. Once the results are known, the treatment plan should be adjusted in a timely manner if necessary.
Manufacturer:

Lunan BETTER Pharmaceutical Co., Ltd.

Related Ingredients
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.